Atara Biotherapeutics, Inc. (LON:0HIY)
London
· Delayed Price · Currency is GBP · Price in USD 6.52
-0.76 (-10.44%)
At close: May 13, 2025
Atara Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 128.94 | 8.57 | 63.57 | 20.34 | - | Upgrade
|
| Revenue Growth (YoY) | 1404.02% | -86.52% | 212.55% | - | - | Upgrade
|
| Cost of Revenue | 168.74 | 228.05 | 269.99 | 282 | 244.65 | Upgrade
|
| Gross Profit | -39.8 | -219.48 | -206.42 | -261.66 | -244.65 | Upgrade
|
| Selling, General & Admin | 38.53 | 49.8 | 68.13 | 78.8 | 64.4 | Upgrade
|
| Operating Expenses | 38.53 | 49.8 | 68.13 | 78.8 | 64.4 | Upgrade
|
| Operating Income | -78.33 | -269.28 | -274.55 | -340.46 | -309.05 | Upgrade
|
| Interest Expense | -4.62 | -5.29 | -0.37 | - | - | Upgrade
|
| Interest & Investment Income | 2.11 | 5.43 | 3.06 | 2.14 | 3.28 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.53 | -0.25 | -0.7 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -80.31 | -269.38 | -272.56 | -338.33 | -305.78 | Upgrade
|
| Merger & Restructuring Charges | -5.11 | -6.73 | -5.96 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -1.77 | -0.83 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 50.24 | - | - | Upgrade
|
| Pretax Income | -85.42 | -276.11 | -228.29 | -340.1 | -306.61 | Upgrade
|
| Income Tax Expense | -0.01 | 0.02 | 0.01 | 0.05 | 0.02 | Upgrade
|
| Net Income | -85.4 | -276.13 | -228.3 | -340.14 | -306.62 | Upgrade
|
| Net Income to Common | -85.4 | -276.13 | -228.3 | -340.14 | -306.62 | Upgrade
|
| Shares Outstanding (Basic) | 7 | 4 | 4 | 4 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 7 | 4 | 4 | 4 | 3 | Upgrade
|
| Shares Change (YoY) | 76.77% | 3.83% | 8.88% | 26.63% | 44.17% | Upgrade
|
| EPS (Basic) | -11.41 | -65.19 | -55.96 | -90.78 | -103.63 | Upgrade
|
| EPS (Diluted) | -11.41 | -65.19 | -55.96 | -90.78 | -103.63 | Upgrade
|
| Free Cash Flow | -68.96 | -194.2 | -274.62 | -231.1 | -185.27 | Upgrade
|
| Free Cash Flow Per Share | -9.21 | -45.84 | -67.32 | -61.68 | -62.62 | Upgrade
|
| Gross Margin | -30.87% | - | - | - | - | Upgrade
|
| Operating Margin | -60.75% | -3140.98% | -431.86% | -1673.85% | - | Upgrade
|
| Profit Margin | -66.23% | -3220.88% | -359.12% | -1672.28% | - | Upgrade
|
| Free Cash Flow Margin | -53.49% | -2265.25% | -431.98% | -1136.19% | - | Upgrade
|
| EBITDA | -73.28 | -264.45 | -268.9 | -331.12 | -300.72 | Upgrade
|
| EBITDA Margin | -56.83% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 5.05 | 4.83 | 5.65 | 9.35 | 8.33 | Upgrade
|
| EBIT | -78.33 | -269.28 | -274.55 | -340.46 | -309.05 | Upgrade
|
| EBIT Margin | -60.75% | - | - | - | - | Upgrade
|
| Revenue as Reported | 128.94 | 8.57 | 63.57 | - | - | Upgrade
|
Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.